Recombinant Anti-CD46 antibody [EPR4014] (ab108307)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4014] to CD46
- Suitable for: WB, IHC-P
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-CD46 antibody [EPR4014]
See all CD46 primary antibodies -
Description
Rabbit monoclonal [EPR4014] to CD46 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt or IP -
Species reactivity
Reacts with: Human
Predicted to work with: Rabbit -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Wild-type HAP1 cell lysate. MOLT-4, Jurkat, HeLa and K562 cell lysates. IHC-P: Human thyroid gland carcinoma, colonic adenocarcinoma, breast carcinoma, kidney, breast, uterus, placenta and tonsil tissue.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR4014 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab108307 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 44 kDa.
|
|
IHC-P | (1) |
1/500 - 1/1000. Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 44 kDa. |
IHC-P
1/500 - 1/1000. Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol. |
Target
-
Function
Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a costimulatory factor for T-cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity. A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype in T-cells by binding to CD46. -
Tissue specificity
Expressed by all cells except erythrocytes. -
Involvement in disease
Defects in CD46 are a cause of susceptibility to hemolytic uremic syndrome atypical type 2 (AHUS2) [MIM:612922]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Patients with CD46 mutations seem to have an overall better prognosis compared to patients carrying CFH mutations. -
Sequence similarities
Contains 4 Sushi (CCP/SCR) domains. -
Domain
Sushi domains 1 and 2 are required for interaction with human adenovirus B PIV/FIBER protein and with Measles virus H protein. Sushi domains 2 and 3 are required for Herpesvirus 6 binding. Sushi domain 3 is required for Neisseria binding. Sushi domains 3 and 4 are required for interaction with Streptococcus pyogenes M protein and are the most important for interaction with C3b and C4b. -
Post-translational
modificationsN-glycosylated on Asn-83; Asn-114 and Asn-273 in most tissues, but probably less N-glycosylated in testis. N-glycosylation on Asn-114 and Asn-273 is required for cytoprotective function. N-glycosylation on Asn-114 is required for Measles virus binding. N-glycosylation on Asn-273 is required for Neisseria binding. N-glycosylation is not required for human adenovirus binding.
Extensively O-glycosylated in the Ser/Thr-rich domain. O-glycosylation is required for Neisseria binding but not for Measles virus or human adenovirus binding.
In epithelial cells, isoforms B/D/F/H/J/L/3 are phosphorylated by YES1 in response to infection by Neisseria gonorrhoeae; which promotes infectivity. In T-cells, these isoforms may be phosphorylated by Lck. -
Cellular localization
Cytoplasmic vesicle > secretory vesicle > acrosome inner membrane. Inner acrosomal membrane of spermatozoa. Internalized upon binding of Measles virus, Herpesvirus 6 or Neisseria gonorrhoeae, which results in an increased susceptibility of infected cells to complement-mediated injury. In cancer cells or cells infected by Neisseria, shedding leads to a soluble peptide. - Information by UniProt
-
Database links
- Entrez Gene: 4179 Human
- Omim: 120920 Human
- SwissProt: P15529 Human
- Unigene: 510402 Human
-
Alternative names
- AHUS2 antibody
- Antigen defined by monoclonal antibody TRA 2 10 antibody
- Antigen identified by monoclonal antibody TRA 2 10 antibody
see all
Images
-
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: CD46 knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: K562 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab108307 observed at 50-70 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab108307 was shown to specifically react with when CD46 knockout samples were used. Wild-type and CD46 knockout samples were subjected to SDS-PAGE. ab108307 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging. -
ab108307, at 1/500 dilution, staining CD46 in paraffin-embedded human tonsil tissue.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
-
ab108307, at 1/500 dilution, staining CD46 in paraffin-embedded human kidney tissue
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
-
All lanes : Anti-CD46 antibody [EPR4014] (ab108307) at 1/1000 dilution
Lane 1 : MOLT-4 (Human lymphoblastic leukemia cell line) cell lysate
Lane 2 : Jurkat (Human T cell leukemia cell line from peripheral blood) cell lysate
Lane 3 : HeLa (Human epithelial cell line from cervix adenocarcinoma) cell lysate
Lane 4 : K562 (Human chronic myelogenous leukemia cell line from bone marrow) cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat anti-rabbit HRP conjugate at 1/2000 dilution
Predicted band size: 44 kDa -
ab108307 showing positive staining in human normal placenta tissue.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
-
ab108307 showing positive staining in human normal uterus tissue.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
-
ab108307 showing positive staining in human thyroid gland carcinoma tissue.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
-
ab108307 showing positive staining in human colonic adenocarcinoma tissue.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
-
ab108307 showing positive staining in human breast carcinoma tissue.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
-
ab108307 showing positive staining in human normal breast tissue.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (14)
ab108307 has been referenced in 14 publications.
- Ma D et al. Kidney transplantation from triple-knockout pigs expressing multiple human proteins in cynomolgus macaques. Am J Transplant 22:46-57 (2022). PubMed: 34331749
- Wang J et al. Patient with CATSPER3 mutations-related failure of sperm acrosome reaction with successful pregnancy outcome from intracytoplasmic sperm injection (ICSI). Mol Genet Genomic Med 9:e1579 (2021). PubMed: 33350607
- Huang Y et al. A SIRPa-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol Oncol 14:657-668 (2020). PubMed: 31899582
- Banadakoppa M et al. Complement inhibitor Crry expression in mouse placenta is essential for maintaining normal blood pressure and fetal growth. PLoS One 15:e0236968 (2020). PubMed: 32745140
- Samy KP et al. The role of human CD46 in early xenoislet engraftment in a dual transplant model. Xenotransplantation 26:e12540 (2019). PubMed: 31219218